J Soh
Overview
Explore the profile of J Soh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
309
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wilson S, Li C, Ramos-Padron E, Nesbo C, Soh J, Sensen C, et al.
J Biotechnol
. 2016 Jul;
235:187-96.
PMID: 27378620
Oil sands tailings ponds store the waste slurry generated by extracting bitumen from surface-mined oil (tar) sands ores. The ponds support diverse microbial communities involved in element cycling, greenhouse gas...
2.
Essola B, Jissendi-Tchofo P, Mfam W, Ngongang C, Soh J, Soh Mba L, et al.
Acta Chir Belg
. 2015 May;
114(4):276-9.
PMID: 26021424
We report the case of a male African patient who presented at day 8 of life with recurrent episodes of proximal small intestine occlusion, which was treated conservatively, because of...
3.
Tran U, Rajarajacholan U, Soh J, Kim T, Thalappilly S, Sensen C, et al.
Cell Death Dis
. 2015 Mar;
6:e1668.
PMID: 25741593
ING1b is a tumor suppressor that affects transcription, cell cycle control and apoptosis. ING1b is deregulated in disease, and its activity is closely linked to that of p53. In addition...
4.
Sunaga N, Kaira K, Imai H, Shimizu K, Nakano T, Shames D, et al.
Oncogene
. 2012 Sep;
32(34):4034-42.
PMID: 22964644
KRAS mutations are one of the most common driver mutations in non-small-cell lung cancer (NSCLC) and finding druggable target molecules to inhibit oncogenic KRAS signaling is a significant challenge in...
5.
Toumpanakis C, Garland J, Marelli L, Srirajaskanthan R, Soh J, Davies P, et al.
Aliment Pharmacol Ther
. 2009 Jul;
30(7):733-40.
PMID: 19573169
Background: Octreotide LAR is an established treatment for malignant carcinoid syndrome. However, studies with large number of patients and long follow-up are lacking. Aim: To present long-terms results with octreotide...
6.
Naya Y, Ochiai A, Soh J, Kawauchi A, Miki T
Int J Impot Res
. 2008 Oct;
20(6):574-7.
PMID: 18923414
Recently, the association between motorcycling and erectile dysfunction (ED) has been reported. Also, lower urinary tract symptoms (LUTS) were reported to be associated with ED. The aim of this study...
7.
Chapidze G, Enquobahrie D, Kapanadze S, Dolidze N, Soh J, Williams M
Georgian Med News
. 2007 Oct;
(148-149):20-5.
PMID: 17921537
Unlabelled: Thyroid dysfunction as an important cardiovascular risk factor, is not well characterized among cardiology patients of Georgia. Further, a consensus has not been reached about the relationships between thyroid...
8.
Soh J, Naya Y, Ushijima S, Naitoh Y, Ochiai A, Mizutani Y, et al.
Arch Androl
. 2006 Apr;
52(3):163-8.
PMID: 16574596
Sildenafil is most effective in men with mild-to-moderate ED, but not severe ED in Japan. In order to evaluate the efficacy of sildenafil, we conducted the present study using the...
9.
Ochiai A, Naya Y, Soh J, Ishida Y, Ushijima S, Mizutani Y, et al.
Int J Impot Res
. 2006 Feb;
18(4):396-9.
PMID: 16452997
The aim of the present study was to evaluate the relationship between motorcycling and erectile dysfunction (ED). We investigated the relationship between motorcycling and erectile function using the 5-items version...
10.
Ochiai A, Naya Y, Soh J, Ishida Y, Mizutani Y, Kawauchi A, et al.
Int J Impot Res
. 2005 Apr;
17(4):339-42.
PMID: 15829991
The aim of this study was to assess the efficacy of sildenafil as the first-step tool for erectile dysfunction (ED) in Japanese males. Between March 1999 and March 2003, 281...